Compare PT Telekomunikasi Indonesia Tbk (TLK) vs Tango Therapeutics Inc. (TNGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
PT Telekomunikasi Indonesia Tbk vs Tango Therapeutics Inc. — how do they compare? PT Telekomunikasi Indonesia Tbk trades at $12.61 (market cap $12.31B), while Tango Therapeutics Inc. trades at $22.23 (market cap $3.75B). The key difference: PT Telekomunikasi Indonesia Tbk is far larger — about 3.3× Tango Therapeutics Inc.'s market cap, and PT Telekomunikasi Indonesia Tbk pays a 9.66% dividend while Tango Therapeutics Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold PT Telekomunikasi Indonesia Tbk for 1 Days and Tango Therapeutics Inc. for 0 Days on average.
| TLK | TNGX | |
|---|---|---|
Market Cap | $12.31B | $3.75B |
Volume | 964,895 | 9,619,106 |
Sector | Media | Health |
52-Week High | $23.43 | $32.90 |
52-Week Low | $12.42 | $7.50 |
Typical Hold Time | 1 Days | 0 Days |
Enterprise Value | $13.67B | $2.77B |
Dividend Yield | 9.66% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TLK trades at $12.65, down 1.02% on the day, with a bearish technical signal driven by moving averages. The stock shows mixed earnings performance with two recent misses but a Q2 2026 beat. Fundamentals remain solid with a 66.88% gross margin and attractive valuation at P/E of 12.72 and EV/EBITDA of 3.27. Recent news includes a 52-week low hit in September 2026 and institutional buying activity.
The outlook is cautious with 100% hold ratings from analysts and bearish technical indicators. Investment opportunity lies in deep value metrics and positive 5G developments, but risks include earnings volatility and competitive pressures in the telecommunications sector.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About PT Telekomunikasi Indonesia Tbk
Telkom Indonesia provides mobile, fixed-line, broadband, and digital services in Indonesia. Its businesses include Telkomsel, which serves the country’s mobile market.
Read more on TLK →About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →
